Kontafarma China Holdings (HKSE:01312) Total Liabilities: HK$588.9 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Kontafarma China Holdings Total Liabilities?

Kontafarma China Holdings HKSE:01312 +3.13% Total Liabilities is HK$588.9 Mil as of Dec. 2025. The stock has 5 warning signs investors should review.

Kontafarma China Holdings's Total Liabilities for the quarter that ended in Dec. 2025 was HK$588.9 Mil.

Kontafarma China Holdings's quarterly Total Liabilities declined from Dec. 2024 (HK$625.90 Mil) to Jun. 2025 (HK$532.12 Mil) but then increased from Jun. 2025 (HK$532.12 Mil) to Dec. 2025 (HK$588.92 Mil).

Kontafarma China Holdings's annual Total Liabilities declined from Dec. 2023 (HK$665.39 Mil) to Dec. 2024 (HK$625.90 Mil) and declined from Dec. 2024 (HK$625.90 Mil) to Dec. 2025 (HK$588.92 Mil).

Kontafarma China Holdings Total Liabilities Historical Data

* Premium members only.

The historical data trend for Kontafarma China Holdings's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kontafarma China Holdings Total Liabilities Chart

Kontafarma China Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,220.99 964.16 665.39 625.90 588.92

Kontafarma China Holdings Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 665.39 631.16 625.90 532.12 588.92

Kontafarma China Holdings Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Kontafarma China Holdings's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=462.8+(74.925+51.197
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=588.9

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=1065.179-476.257
=588.9

Kontafarma China Holdings's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=462.8+(74.925+51.197
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=588.9

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=1065.179-476.257
=588.9

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of HK$588.9 Mil mean?
Kontafarma China Holdings (HKSE:01312) has a Total Liabilities of HK$588.9 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Kontafarma China Holdings and its competitors.
Is Kontafarma China Holdings' Total Liabilities too high?
Kontafarma China Holdings' current Total Liabilities is HK$588.9 Mil.
How does Kontafarma China Holdings' Total Liabilities compare to ZTS?
Kontafarma China Holdings' Total Liabilities of HK$588.9 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Kontafarma China Holdings and its competitors. Kontafarma China Holdings's current Total Liabilities is HK$588.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kontafarma China Holdings stock overvalued right now?
Based on GuruFocus' analysis, Kontafarma China Holdings (HKSE:01312) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.04, compared to a current price of HK$0.03 — trading 17.5% below its estimated fair value. The current Total Liabilities is HK$588.9 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Kontafarma China Holdings (HKSE:01312), the current Total Liabilities is HK$588.9 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kontafarma China Holdings Business Description

Address 30 Harbour Road, Room 12A15-12A20, 12A Floor, Sun Hung Kai Centre, Wanchai, Hong Kong, HKG
Kontafarma China Holdings Ltd and its subsidiaries are principally engaged in the pharmaceutical and fitness business. The Group manufactures and sells prescription drugs, including chemical drugs, traditional Chinese medicine prescriptions, active pharmaceutical ingredients, and API intermediates in China, and operates fitness centres, provides fitness and health consultation services, and operates a franchise business for royalty fee income. Its segments are the pharmaceutical business, which generates maximum revenue, and the fitness business. The Group operates in Mainland China, Singapore, Taiwan, and other regions, with maximum revenue from Mainland China.